Chronix Biomedical, Inc., a US based developer of blood-based molecular diagnostics and blood tests primarily for the screening and monitoring of cancer, has announced that it will present data relating to its cell-free DNA copy number instability (CNI) diagnostic at the American Association for Cancer Research (‘AACR’) Annual Meeting 2016 in New Orleans, Louisiana on 19 April 2016.
The following abstract will be presented during the poster session: Changes in tumor cell-free DNA copy number instability (CNI) predict therapeutic response in metastatic cancers.
The study was conducted by Dr. Glen Weiss and colleagues at Cancer Treatment Centers of America at Western Regional Medical Center in Goodyear, AZ.
The abstract is scheduled to be presented from 08 to 12 on Tuesday, 19 April 2016 at the AACR 2016 conference.
AACR 2016 will take place on 16-20 April 2016 at the Ernest N. Morial Convention Center, New Orleans, Louisiana, USA.
The American Association for Cancer Research Annual Meeting is an event for cancer researchers and the broader cancer community. This year's theme, "Delivering Cures Through Cancer Science," reinforces the inextricable link between research and advances in patient care. The theme will be evident throughout the meeting as the latest, most exciting discoveries are presented in every area of cancer research. There will be a number of presentations that include exciting new data from cutting-edge clinical trials as well as companion presentations that spotlight the science behind the trials and implications for delivering improved care to patients.